Your browser doesn't support javascript.
loading
Peroperative administration of tranexamic acid in sleeve gastrectomy to reduce hemorrhage: a double-blind randomized controlled trial.
't Hart, J W H; Noordman, B J; Wijnand, J M A; Biter, L U; Verbrugge, S J C; Birnie, E; Dunkelgrun, M; Huisbrink, J; Apers, J A.
Afiliação
  • 't Hart JWH; Department of Surgery, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands. j.hart@franciscus.nl.
  • Noordman BJ; Department of Surgery, Erasmus University Medical Centre, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. j.hart@franciscus.nl.
  • Wijnand JMA; Department of Surgery, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands.
  • Biter LU; Department of Surgery, Erasmus University Medical Centre, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Verbrugge SJC; Department of Surgery, Franciscus Gasthuis & Vlietland, Kleiweg 500, 3045 PM, Rotterdam, The Netherlands.
  • Birnie E; Department of Surgery, Tulp Medisch Centrum, Zwijndrecht, The Netherlands.
  • Dunkelgrun M; Department of Anesthesiology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Huisbrink J; Department of Statistics and Education, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Apers JA; Department of Genetics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Surg Endosc ; 37(10): 7455-7463, 2023 10.
Article em En | MEDLINE | ID: mdl-37400687
ABSTRACT

INTRODUCTION:

In metabolic surgery, hemorrhage is the most common major complication. This study investigated whether peroperative administration of tranexamic acid (TXA) reduced the risk of hemorrhage in patients undergoing laparoscopic sleeve gastrectomy (SG).

METHODS:

In this double-blind randomized controlled trial, patients undergoing primary SG in a high-volume bariatric hospital were randomized (11) to receive 1500-mg TXA or placebo peroperatively. Primary outcome measure was peroperative staple line reinforcement using hemostatic clips. Secondary outcome measures were peroperative fibrin sealant use and blood loss, postoperative hemoglobin, heart rate, pain, major and minor complications, length of hospital stay (LOS), side effects of TXA (i.e., venous thrombotic event (VTE)) and mortality.

RESULTS:

In total, 101 patients were analyzed and received TXA (n = 49) or placebo (n = 52). There was no statistically significant difference in hemostatic clip devices used in both groups (69% versus 83%, p = 0.161). TXA administration showed significant positive changes in hemoglobin levels (millimoles per Liter; 0.55 versus 0.80, p = 0.013), in heart rate (beats per minute; -4.6 versus 2.5; p = 0.013), in minor complications (Clavien-Dindo ≤ 2, 2.0% versus 17.3%, p = 0.016), and in mean LOS (hours; 30.8 versus 36.7, p = 0.013). One patient in the placebo-group underwent radiological intervention for postoperative hemorrhage. No VTE or mortality was reported.

CONCLUSION:

This study did not demonstrate a statistically significant difference in use of hemostatic clip devices and major complications after peroperative administration of TXA. However, TXA seems to have positive effects on clinical parameters, minor complications, and LOS in patients undergoing SG, without increasing the risk of VTE. Larger studies are needed to investigate the effect of TXA on postoperative major complications.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Tranexâmico / Antifibrinolíticos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácido Tranexâmico / Antifibrinolíticos Idioma: En Ano de publicação: 2023 Tipo de documento: Article